Galinpepimut-S (WT1)

Term: Galinpepimut-S (WT1)Definition: Galinpepimut-S (WT1) is an experimental cancer vaccine designed to stimulate the immune system to target cells expressing the Wilms' Tumor 1 (WT1) protein, which is overexpressed in various cancers, including mesothelioma linked to asbestos exposure.Phonetic Pronunciation: (gal-in-PEP-i-mut S)Origin: The term "Galinpepimut-S" is derived from its components and purpose. "Galin" refers to the company Galena Biopharma, which developed the vaccine. "Pepimut" is a combination of "peptide" and "mutant," indicating the vaccine's use of a peptide derived from the WT1 protein. "S" denotes it as a specific formulation. The WT1 part of the name comes from Wilms' Tumor 1, a gene first identified in a type of kidney cancer.Significance in Asbestos Context: Galinpepimut-S is significant in the context of asbestos-related diseases because it targets the WT1 protein, which is overexpressed in mesothelioma, a cancer strongly associated with asbestos exposure. This vaccine represents a potential therapeutic option for patients with asbestos-induced cancers, offering hope for improved outcomes and quality of life.Example Sentence: "Clinical trials are underway to assess the efficacy of Galinpepimut-S (WT1) in patients with mesothelioma caused by asbestos exposure."Related Terms: Mesothelioma, immunotherapy, WT1 protein, cancer vaccine, asbestos-related disease.Notes: - Galinpepimut-S is still under investigation and not yet approved for general use. - It is specifically designed to target the WT1 protein, which is not unique to asbestos-related cancers but is relevant in this context. - The vaccine's development is part of a broader effort to harness the immune system in fighting cancer.